OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAetnaPolicy 0698

Prostate Biopsy

Customize your policy alerts

Sign up for Aetna Policy 0698 alerts

Get alerted when Policy 0698 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage policy for various prostate biopsy approaches (transperineal stereotactic template-guided saturation, transrectal ultrasound-guided, MRI-guided, and others) describing medical necessity, investigational procedures, coding guidance, and limitations for Aetna members and providers.

Policy Summary

PayerAetna

PolicyProstate Biopsy

Policy CodePolicy 0698

Change TypeNo material clinical or coverage changes

Effective DateJan 31, 2006

Last ReviewSep 26, 2023

Next Review DateJul 25, 2024

Key ActionDocument indication and prior biopsy history when requesting coverage for saturation or MRI-guided prostate biopsy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

30-80cores typically taken in transperineal template-guided saturation biopsy

10-12standard TRUS cores

37.6%MRI-GB detection rate (meta-analysis)

46 studiesstudies in meta-analysis

09/26/2023last review

Coverage and Medical Necessity Criteria

Medical necessity criteria by biopsy type

Covered when ANY of the specific procedural indications are met (grouped by biopsy type):

Transperineal stereotactic template-guided saturation biopsy: Medically necessary for men with 2 prior negative prostate biopsies and a persistently rising PSA OR men with histologic findings of atypia or high-grade prostatic intraepithelial neoplasia (PIN) on prior biopsy.

Saturation biopsy considered experimental/investigational for other indications (e.g., surveillance/watchful waiting).

TRUS-guided prostate biopsy for diagnosis: For diagnosis when serum prostate-specific antigen (PSA) level and/or digital rectal examination (DRE) is abnormal.

TRUS-guided biopsy for follow-up/active surveillance: Life expectancy > 5 years AND repeat DRE abnormal and/or rising PSA and/or suspicious MRI AND repeat biopsy performed to support changes in treatment or definitive treatment.life expectancy >5 years

Policy Summary

PayerAetna

PolicyProstate Biopsy

Policy CodePolicy 0698

Change TypeNo material clinical or coverage changes

Effective DateJan 31, 2006

Last ReviewSep 26, 2023

Next Review DateJul 25, 2024

Key ActionDocument indication and prior biopsy history when requesting coverage for saturation or MRI-guided prostate biopsy.

SourceLink

On This Page

MRI-guided biopsy criteria

Covered when ALL of the following are met for MRI-guided (transperineal or transrectal, in-bore or fusion) biopsy:

MRI-guided biopsy for diagnosis: Prior prostate biopsy AND repeat DRE abnormal and/or rising PSA.

Includes in‑bore (direct) MRI-TB and MRI-TRUS fusion approaches; only suspicious lesions on mpMRI are targeted.

MRI-guided biopsy for follow-up/active surveillance: Life expectancy > 5 years AND repeat DRE abnormal and/or rising PSA and/or suspicious MRI AND repeat biopsy performed to support changes in treatment or definitive treatment.life expectancy >5 years

Documentation should include mpMRI lesion identification (e.g., PI-RADS) and prior biopsy history.

Re-biopsy selection

Coverage considerations for biopsy approaches in men with prior negative biopsies and persistent suspicion

Re-biopsy with saturation or MRI-guided approaches: Consider saturation biopsy (≥20 cores including transition zone) or MRI-guided biopsy for men at high risk with multiple prior negative biopsies and persistently rising PSA or ongoing clinical suspicion.clinical judgement and prior negative extended biopsies

NCCN and NICE guidance support considering saturation or transperineal/MRI approaches in selected re-biopsy cases; saturation reserved for repeated negatives.

Modality comparative outcomes

Comparative detection performance

Modality detection rates: In re-biopsy studies MRI-guided biopsy and transperineal template biopsy show similar overall cancer detection and may have higher detection than transrectal saturation biopsy in some analyses; MRI-guided biopsy can achieve comparable detection with fewer cores but may miss anterior or peri-urethral lesions.study-level heterogeneity

Meta-analysis reported detection rates: TS-B 30.0%, TP-B 36.8%, MRI-B 37.6%; individual comparative studies report variable findings for combined strategies.

Harms and diagnostic consequences

Potential harms and downstream effects

Saturation biopsy morbidity and impact: Extensive/saturation biopsy protocols can increase morbidity (eg, marked hematuria, urinary retention) and may lead to increased detection of insignificant cancers or overestimation of Gleason score compared with whole-mount pathology.depends on extent of sampling

Simon et al reported median cores ~64 with 45% cancer detection and notable hematuria; autopsy and cohort studies found no clear detection benefit over fewer cores and potential Gleason overestimation.

Adjunct/experimental methods

Adjunct and investigational technologies

Experimental adjuncts: Optical/fluorescence spectroscopy–guided biopsy needles have shown promising sensitivity, specificity and NPV in small feasibility studies but remain investigational; micro‑ultrasound (PRI‑MUS) and contrast-enhanced ultrasound techniques are also considered investigational. DNA specimen provenance assays (eg, know error®) are considered laboratory quality-control and are not separately reimbursed.research/validation required

These approaches are listed as experimental/investigational and not supported for routine clinical use in this policy.

Aetna considers the following procedures experimental and investigational because their effectiveness has not been established: contrast-enhanced ultrasound–targeted prostate biopsy, micro‑ultrasound (MicroUS) guided prostate biopsy (e.g., PRI‑MUS), spectral analysis of prostate tissue by fluorescence spectroscopy, and ultrasound superb microvascular imaging for guiding targeted prostate biopsy. These modalities remain investigational pending further evidence of clinical utility and standardized implementation.

Guidance indicates that transperineal template biopsy has a role in patients with prior negative or equivocal biopsies where diagnostic yield may be increased, but current evidence does not support its routine use as a mapping technique to determine exact tumor location and extent to guide focal therapy or as part of active surveillance. Use of transperineal template mapping for those purposes should be confined to settings with appropriate clinical governance, informed consent, audit, or research oversight.

Published studies of novel imaging‑guided biopsy approaches note several important limitations that affect interpretation and generalizability: operator and observer dependence (particularly for MicroUS interpretation), heterogeneity in MRI scanner strength and imaging protocols across centers, lack of standardized procedures for contrast‑enhanced ultrasound–guided biopsy, and absence of an ideal reference standard in some investigations. These factors reduce certainty about comparative performance and underscore the need for further standardized, multicenter validation with longer‑term outcomes.

Clinical Policy Bulletins are developed to assist in administering plan benefits and provide only a partial, general description of plan or program benefits. They do not constitute a contract or medical advice. Coverage determinations, exclusions, and any prior authorization requirements depend on the member’s specific plan documents and should be confirmed against the applicable plan language and administrative rules.

Transperineal stereotactic template‑guided saturation biopsy is medically necessary only for the specific indications listed in this policy (for example, men with two prior negative biopsies and persistently rising PSA, or men with prior biopsy showing atypia or high‑grade PIN). Use of transperineal stereotactic saturation biopsy for indications other than those specified in the policy (for example, routine surveillance or watchful waiting of persons with a known positive prostate biopsy) is considered experimental and investigational and is not supported by sufficient evidence.

Saturation biopsy protocols are not appropriate for initial screening or initial diagnostic biopsy. The policy and contemporary reviews indicate that saturation biopsy is intended primarily for re‑biopsy after prior negative TRUS biopsies when clinical suspicion persists. Initial diagnostic strategies should use extended schemes (e.g., 12 cores) or other standard approaches before considering a saturation protocol.

Coding Guidance

CPT codes covered if selection criteria are metCPTCovered

45342	Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s).
55706	Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance.
72195	Magnetic resonance (e.g. proton) imaging, pelvis.
72196	Magnetic resonance (e.g. proton) imaging, pelvis.
72197	Magnetic resonance (e.g. proton) imaging, pelvis.

CPT codes not covered / investigationalCPTNot Covered

0443T

Real-time spectral analysis of prostate tissue by fluorescence spectroscopy, including imaging guidance.

Other related CPT codesCPT

55700	Biopsy, prostate; needle or punch, single or multiple, any approach.
84152	Prostate specific antigen (PSA); complexed (direct measurement).
84153	Prostate specific antigen (PSA); total.
84154	Prostate specific antigen (PSA); free.

HCPCS codes covered if selection criteria are metHCPCSCovered

G0416

Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method.

Other HCPCS related codesHCPCS

G0102	Prostate cancer screening; digital rectal examination.
G0103	Prostate cancer screening; prostate specific antigen test (PSA).

ICD-10 codes related to coverageICD-10

C61	Malignant neoplasm of prostate.
D07.5	Carcinoma in situ of prostate [PIN III].
N42.30	Dysplasia of prostate [PIN I or II].
Z12.5	Encounter for screening for malignant neoplasm of prostate.

Laboratory / specimen provenance testingmixed

not specified

DSPA / know error® DNA specimen provenance assay (manufacturer-specific forensic DNA test) — described as laboratory quality control and not separately reimbursed

MRI-guided and MRI/US fusion biopsymixed

not specified

MRI-guided prostate biopsy (in-bore/direct MRI-TB, MRI/US fusion, cognitive fusion) — procedures and core counts vary by study

Saturation and template mapping biopsiesmixed

not specified

Saturation biopsy schemes (transrectal saturation biopsy TS-B, template transperineal saturation biopsy TTMB) — core counts in studies ranged from ~18 to ≥24 with some series reporting median cores up to 64 in very extensive protocols

Experimental/adjunct diagnostic technologiesmixedExperimental

not specified

Optical/fluorescence spectroscopy–guided biopsy needle and other experimental adjunct devices — described in small studies and considered investigational

No explicit CPT/HCPCS/ICD-10 codes in this document portionmixed

No codes listed

Saturation biopsy core count threshold — key values

Saturation biopsy core count threshold≥20 cores (saturation biopsies defined as template schemes with greater than or equal to 20 cores, including transition zone)

Typical extreme sampling rangesStudies/series describe very extensive protocols (median ≈64 cores; individual reports 30–80 cores)

Role in re-biopsyReserved for repeat biopsies in patients with persistent suspicion after prior negative extended biopsies (NCCN guidance)

PI-RADS threshold used for enrollment — key values

PI-RADS enrollment thresholdPI-RADS ≥ 3 used for prospective enrollment in MicroUS and MRI‑targeted study cohorts (patients had at least one PI-RADS ≥3 lesion)

Use in study triagePatients with PI-RADS 3–5 underwent MRI-guided procedures in comparative studies; lower PI-RADS (1–2) led to different biopsy pathways

Documentation relevancePre-biopsy mpMRI PI-RADS scoring is emphasized for decision-making and documentation when MRI-guided biopsy is considered

Provider Responsibilities and Billing Alerts

Billing Rule

Codes affected by selection criteria

Certain CPT and HCPCS codes in this policy are covered only when the selection criteria in the policy are met. Verify that documentation supports the indication before billing these codes.

CPT codes affected by selection criteria: 45342, 55706, 72195-72197
HCPCS code affected by selection criteria: G0416
ICD-10/diagnosis codes must support medical necessity (e.g., C61, D07.5, N42.30–N42.39)

Prior Authorization

Prior authorization

This policy excerpt does not specify any formal prior authorization requirements. Providers should follow plan-specific prior authorization processes and any payer portals or instructions for submitting pre-service reviews when applicable.

Prior authorization not specified in this excerpt
No explicit prior authorization statement in the provided text

Note

Prior authorization guidance

Clinical Policy Bulletins are administrative tools to assist in applying plan benefits. Providers are responsible for following the plan’s prior authorization processes and any submission instructions in network/practice-specific systems.

Clinical Policy Bulletins assist in administering plan benefits — check plan portals for prior auth processes
Providers are responsible for medical administration decisions and for obtaining any required authorizations per member plan

Denial Risk

Investigational procedures — denial risk

Procedures identified as experimental or investigational in this policy may be denied as not medically necessary. Ensure that indications and supporting evidence are documented if performing or billing for these procedures.

Experimental/Investigational (denial risk): Contrast‑enhanced ultrasound‑targeted prostate biopsy
Experimental/Investigational (denial risk): Micro‑ultrasound guided prostate biopsy (e.g., PRI‑MUS)
Experimental/Investigational (denial risk): Real‑time spectral analysis of prostate tissue by fluorescence spectroscopy (0443T)
Experimental/Investigational (denial risk): Ultrasound superb microvascular imaging for targeted biopsy

Billing Rule

DSPA / know error® reimbursement stance

The know error® DNA Specimen Provenance Assay (DSPA) is considered part of the laboratory’s quality control and is not separately reimbursed. Do not bill this test as a separately reimbursable service when performed as part of biopsy specimen processing.

DSPA/know error® reimbursement stance: not separately reimbursed; considered laboratory quality control
Treat as integral to the biopsy/pathology workflow; include in laboratory service bundle billing when applicable

Documentation Required

Clinical indication and biopsy sequencing documentation

Document the clinical indication clearly in the medical record to support medical necessity for biopsy procedures. Include prior biopsy history, reason for re‑biopsy, PSA trends, DRE findings, and any atypia or PIN on prior pathology when applicable.

Clinical indication documentation should include: number and results of prior biopsies, PSA trend (rising/values), DRE findings, and prior histologic findings (atypia or high‑grade PIN)
Preferred biopsy sequencing: reserve saturation biopsies (≥20 cores) for patients with repeated negative biopsies but persistent high suspicion

Documentation Required

Documentation for MRI‑guided and re‑biopsy procedures

When MRI‑guided biopsy techniques or re‑biopsy strategies are used, document prior TRUS biopsies (if performed), rationale for choosing MRI‑GB or transperineal approaches, mpMRI findings (including PI‑RADS score), and whether in‑bore, fusion, or cognitive targeting was used.

Documentation for MRI‑guided and re‑biopsy procedures: prior negative TRUS biopsies (when applicable) and clinical rationale for re‑biopsy
Documentation of pre‑biopsy mpMRI findings: record PI‑RADS scoring and the MRI‑targeting method (in‑bore, fusion, cognitive)

Background and Scope

Prostate cancer is a common malignancy and tissue diagnosis requires biopsy. Transperineal stereotactic template‑guided saturation biopsy (TTSB) is an approach that samples the gland extensively; series and guideline descriptions characterize typical sampling schemes in the range of about 30–80 cores in saturation or extensive template protocols. TTSB is proposed principally for men with prior negative biopsies but persistent clinical suspicion (for example, rising PSA, atypia, or high‑grade PIN), where more extensive sampling may improve detection of clinically significant disease.

Key Definitions

TTSB — Transperineal stereotactic template-guided saturation prostate biopsy

DefinitionTransperineal stereotactic template-guided saturation prostate biopsy (TTSB) — transperineal template-guided saturation sampling typically using 30 to 80 cores to evaluate high-risk men with multiple prior negative extended biopsies

Typical indicationsUsed for men with persistently rising PSA, atypia, or high-grade PIN after prior negative biopsies

Sampling approachTemplate-guided stereotactic sampling via transperineal approach to comprehensively sample peripheral and transition zones

TRUS-guided biopsy — Transrectal ultrasound-guided biopsy definition

DefinitionTransrectal ultrasound (TRUS)-guided prostate biopsy — needle cores obtained through rectal wall into the prostate, usually 6–18 cores with 10–12 cores considered standard of care

Standard core count10–12 tissue cores considered standard for initial diagnostic TRUS-guided biopsy

Context of useMain method used to diagnose prostate cancer; extended protocols (e.g., 12–18 cores) are used depending on clinical factors

Clinically insignificant tumor — definition

Definition used in autopsy/biopsy comparative studiesClinically insignificant tumor defined as organ-confined with index tumor volume < 0.5 mL and Gleason score ≤ 6

ImplicationUsed to assess potential over-detection by saturation biopsies versus whole-mount pathology

Study findingIn Delongchamps autopsy series, several insignificant tumors were identified and saturation cores did not increase detection over an 18-core scheme

Clinically significant prostate cancer (csPCA) — study definitions

Study-based definitionClinically significant prostate cancer (csPCA) in cited studies generally defined as Gleason score ≥ 3+4 (Gleason ≥7) or study-specific thresholds for significance

Outcome rolecsPCA used as the primary outcome in comparisons of MRI-guided versus template saturation biopsies

Detection considerationsSome MRI-guided approaches detected similar csPCA rates to template saturation but missed peri-urethral/anterior lesions in subsets

In‑bore MRI‑guided biopsy (MRI‑TB) — definition

DefinitionIn‑bore MRI‑guided biopsy (MRI‑TB) — transrectal biopsy performed with the patient inside the MRI scanner; prior MRI images are fused with contemporaneous MRI to localize and sample targets with serial MRI confirmation of needle placement

Technique featuresRadiologist fuses diagnostic MRI with interventional images (often acquired at 1–1.5T) and performs serial scans to confirm needle location

Sampling strategyOnly suspicious lesions on MRI are sampled; normal‑appearing MRI tissue is typically not obtained

Clinically significant prostate cancer (csPCa) — definition in cited studies

csPCa (grade group approach)Clinically significant prostate cancer often defined in cited studies as Grade Group ≥2 (Gleason ≥3+4) on any core — the target outcome for MRI‑guided and targeted modalities

Meta-analysis findingsMRI‑GB (all techniques combined) detected higher rates of csPCa compared with TRUS‑GB (RR 1.16) in pooled analyses

Technique comparabilityNo significant difference in csPCa detection among MRI‑TB, FUS‑TB, and COG‑TB in some pooled analyses

csPCa — multiple-study definitions

Multiple-study definitionsAcross studies csPCa is defined as Grade Group ≥2 or Gleason score ≥7 depending on the trial or cohort (study‑specific), used as primary diagnostic target

Detection variabilityPooled analyses reported csPCa detection rates around mid‑30% range across MRI techniques with modest between‑technique differences

Clinical implicationDefinitions affect reported detection rates and cross‑study comparability; documentation of the definition used is essential

PRI-MUS — scoring protocol for MicroUS

PRI‑MUS protocolPRI‑MUS is the scoring protocol used with MicroUS (ExactVu) to identify suspicious targets; increasing PRI‑MUS scores predict higher likelihood of csPCa

Study useLughezzani et al used PRI‑MUS prospectively to guide MicroUS targeting in patients with PI‑RADS ≥3 MRI lesions

Predictive valueHigher PRI‑MUS scores were independent predictors of csPCa in reported cohorts (statistically significant)

NCCN — references cited across guideline years

NCCN citationsNational Comprehensive Cancer Network (NCCN) prostate cancer guidelines are cited multiple times across years in the policy references

Guideline roleNCCN guidance informs consideration of saturation biopsy strategies in men with 2 prior negative extended biopsies and persistent PSA rise

Documented versionsReferences include NCCN versions spanning 2007 through 2023 as listed in the reference section

Policy Revision History

2006-01-31effective

Policy effective date as listed in document metadata.

2023-09-26last_reviewLatest

Most recent policy review date recorded in document metadata.

2024-07-25next_review

Next scheduled policy review date recorded in document metadata.